Trinity Biotech

Trinity Biotech Inventory

The Inventory of Trinity Biotech (TRIB) as of Nov 13, 2026 is 18.83 M USD. In the previous year, Inventory was 19.37 M USD — a change of -2.82% (lower).

Inventory

18.83 MUSD

YoY

-2.82%

Last updated:

Inventory of Trinity Biotech is 2025 18.83 M USD. Inventory of Trinity Biotech was 2024 19.37 M USD. It decreases by -2.82% lower compared to the previous year.

The Trinity Biotech Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
30.36 M USD
Jan 1, 2019
32.02 M USD
Jan 1, 2020
30.22 M USD
Jan 1, 2021
29.12 M USD
Jan 1, 2022
22.50 M USD
Jan 1, 2023
19.93 M USD
Jan 1, 2024
19.37 M USD
Jan 1, 2025
18.83 M USD
The Trinity Biotech Inventory history
YEARInventoryYoY
18.83 MUSD-2.82%
19.37 MUSD-2.80%
19.93 MUSD-11.42%
22.50 MUSD-22.73%
29.12 MUSD-3.63%
30.22 MUSD-5.63%
32.02 MUSD+5.47%
30.36 MUSD-7.46%
32.81 MUSD+0.66%
32.59 MUSD-7.22%
35.13 MUSD+4.80%
33.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Inventory of Trinity Biotech is 18.83 M USD in 2025.

Inventory of Trinity Biotech changed from 19.37 M USD to 18.83 M USD, representing a -2.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech